Skip to main content

Advertisement

Table 1 Summary of treatment strategies, peri-partum management and anti-Xa monitoring used by respondents

From: Management of pregnancy associated venous-thromboembolism: a survey of practices

   LMWH Full dose BID LMWH Full dose OD UFH IV UFH SC BID LMWH intermediate dose OD Other
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Acute treatment DVT 62.3 (50–73) 36.2 (25–48) 0 1.4 (0–7) NA 0.14 (0–7)
PE 62.3 (50–73) 29 (19–40) 5.8 (2–13) 1.4 (0–7) NA 1.4 (0–7)
Long-term treatment DVT 36.2 (25–48) 34.8 (24–46) NA 0 23.2 (14–34) 5.8 (2–13)
PE 37.7 (26–49) 36.2 (25–48) NA 0 21.7 (13–32) 4.4 (1–11)
   Weekly Once a month Weekly in special populations* Once a month in special populations* Never Other
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Anti-Xa monitoring Acute treatment 20. 4 (12–31) 26 (16–37) 7.2 (3–15) 15.9 (9–26) 20.4 (12–31) 10.1 (4–19)
Long-term 1.4 (0–7) 17.4 (10–27) 2.9 (0–9.2) 30.4 (20–42) 34.8 (24–46) 13.1 (24–46)
Treatment
   IVC filter + LMWH BID IVC filter + IV UFH LMWH BID UFH SC BID UFH IV Other
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) %
Peri-partum Management VTE > 4 weeks 0 0 53.6 (41–65) 18.8 (11–29) 5.8 (2–13) 21.7 (0–9.2)
VTE <4 and >2 weeks 0 2.9 (0–9.2) 31.9 (21–43) 10.1 (4–19) 39.1 11.7 (5–20)
VTE <2 weeks 21.7 (15–32) 29 (19–40) 10.1 (4–19) 2.9 (0–9.2) 13.1 (6–22) 20.4 (12–31)
  1. Abbreviations: DVT Deep vein thrombosis, PE Pulmonary embolism, VTE Venous thromboembolism, IVC Inferior vena cava filter, LMWH Low molecular weight heparin, UFH Unfractioned heparin, OD once daily, BID Twice daily, IV Intravenous, SC subcutaneous.
  2. *Special populations were defined as extreme body weights >150 kg or < 40 kg or creatinine clearance close to 30 ml/min.